Use of immunoregulatory NK cell populations for predicting the efficacy of antiIL-2R antibodies in multiple sclerosis patients

Details for Australian Patent Application No. 2010313318 (hide)

Owner Abbott Biotherapeutics Corp.

Inventors Sheridan III, James Peter

Agent Davies Collison Cave

Pub. Number AU-A-2010313318

PCT Pub. Number WO2011/053777

Priority 61/256,761 30.10.09 US

Filing date 29 October 2010

Wipo publication date 5 May 2011

International Classifications

G01N 33/50 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

G01N 33/564 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for pre-existing immune complex or autoimmune disease

Event Publications

12 April 2012 PCT application entered the National Phase

  PCT publication WO2011/053777 Priority application(s): WO2011/053777

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010313323-Direct control spinal implant

2010313314-Flexible endoscope with modifiable stiffness